<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>342</serviceExecutionTime><Drug id="54707"><DrugName>PXS-2076</DrugName><DrugSynonyms><Name><Value>PXS-2076</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TNF release inhibitor (rheumatoid arthritis), Pharmaxis</Value></Name><Name><Value>cannabinoid CB2 agonist (rheumatoid arthritis), Pharmaxis</Value></Name><Name><Value>PXS-2030</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PXS-2000</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29072">Pharmaxis Ltd</CompanyOriginator><CompaniesSecondary><Company id="29072">Pharmaxis Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54707" type="Drug"><TargetEntity id="383801" type="siDrug">PXS-2076</TargetEntity></SourceEntity><SourceEntity id="29072" type="Company"><TargetEntity id="4295857111" type="organizationId">Pharmaxis Ltd</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="2581" type="Action"><TargetEntity id="107" type="Mechanism">Cannabinoid CB2 Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00279" type="ciTarget"><TargetEntity id="162460901912693" type="siTarget">Cannabinoid receptor 2</TargetEntity><TargetEntity id="1599581128" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsPrimary><Action id="2581">Cannabinoid CB2 receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="3511">TNF release inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-31T10:39:13.000Z</LastModificationDate><ChangeDateLast>2009-09-02T11:32:52.000Z</ChangeDateLast><AddedDate>2006-01-03T15:23:39.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29072" linkType="Company"&gt;Pharmaxis&lt;/ulink&gt; (formerly Praxis-Australia), was investigating PXS-2076, a cannabinoid CB2 receptor agonist and TNF release inhibitor, for the potential treatment of rheumatoid arthritis (RA). In July 2007, the program was still listed as being in the preclinical stage [&lt;ulink linkID="814654" linkType="Reference"&gt;814654&lt;/ulink&gt;]. However, by  November 2007,  Pharmaxis reported that the program had been discontinued as it was not suitable for pharmaceutical development [&lt;ulink linkID="1038257" linkType="Reference"&gt;1038257&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2005, due to a more favourable pharmaceutical profile, PXS-2076 had replaced PXS-2030 as a drug development candidate [&lt;ulink linkID="643164" linkType="Reference"&gt;643164&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By June 2004, PXS-2076 had been shown to be effective in rodent models of RA [&lt;ulink linkID="643163" linkType="Reference"&gt;643163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;PXS-2076 and PXS-2030 are synthetic compounds, derived from PXS-2000, that have similar cellular and clinical effects to cannabis, without the undesirable psychotropic effects [&lt;ulink linkID="643164" linkType="Reference"&gt;643164&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patent &lt;ulink linkID="PA2952571" linkType="Patent"&gt;WO-2005021547&lt;/ulink&gt; was filed in August 2004, covering the use of benzimidazolyl-benzamide derivative CB2 agonists, including PXS-2030, for inflammatory and immune diseases.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29072">Pharmaxis Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-11-28T00:00:00.000Z</StatusDate><Source id="1038257" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29072">Pharmaxis Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-12-31T00:00:00.000Z</StatusDate><Source id="643148" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00279"><Name>Cannabinoid CB2 receptor</Name><SwissprotNumbers><Swissprot>P34972</Swissprot><Swissprot>P47936</Swissprot><Swissprot>Q9QZN9</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>2 references added [&lt;ulink url="utility.reference?i_reference_id=1284707" linkType="reference" linkID="1284707"&gt;1284707&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=1284709" linkType="reference" linkID="1284709"&gt;1284709&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1758649" number="WO-2005021547" title="Novel cannabinoid CB2 receptor agonists and uses thereof"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmaxis Ltd" id="29072"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>